Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants
Eli Lilly shares ended little changed on Thursday after the drugmaker lined up another research collaboration, this time in autoimmune disease. The stock closed up 0.03% at $1,024.14, as Wall Street finished mixed.
